{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Juhlin CC"],"funding":["Cancerfonden"],"pagination":["401-410"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7665972"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(4)"],"pubmed_abstract":["Neuroendocrine neoplasms (NENs) have traditionally been identified via expression of proteins associated to the regulation of secretory vesicles and granules. We report the clinical usage of the \"second-generation\" proteins ISL LIM homeobox 1 (ISL1), INSM transcriptional repressor 1 (INSM1), and secretagogin (SECG) as immunohistochemical markers of neuroendocrine differentiation since their introduction in clinical routine and compare the results with the established proteins chromogranin A (CGA) and synaptophysin (SYP). In total, 161 tumors, including 139 NENs and 22 \"non-NENs\" (unrelated tumors with an initial suspicion of NEN), were informatively stained for ISL1, and subsets were also interrogated for INSM1 and/or SECG. Diffuse or focal positive immunoreactivity was noted for ISL1 in 9"],"journal":["Endocrine pathology"],"pubmed_title":["Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin."],"pmcid":["PMC7665972"],"funding_grant_id":["Junior Clinical Investigator Award"],"pubmed_authors":["Juhlin CC","Hoog A","Zedenius J"],"additional_accession":[]},"is_claimable":false,"name":"Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin.","description":"Neuroendocrine neoplasms (NENs) have traditionally been identified via expression of proteins associated to the regulation of secretory vesicles and granules. We report the clinical usage of the \"second-generation\" proteins ISL LIM homeobox 1 (ISL1), INSM transcriptional repressor 1 (INSM1), and secretagogin (SECG) as immunohistochemical markers of neuroendocrine differentiation since their introduction in clinical routine and compare the results with the established proteins chromogranin A (CGA) and synaptophysin (SYP). In total, 161 tumors, including 139 NENs and 22 \"non-NENs\" (unrelated tumors with an initial suspicion of NEN), were informatively stained for ISL1, and subsets were also interrogated for INSM1 and/or SECG. Diffuse or focal positive immunoreactivity was noted for ISL1 in 9","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2025-04-05T08:45:05.495Z","creation":"2024-11-09T16:43:40.187Z"},"accession":"S-EPMC7665972","cross_references":{"pubmed":["32813226"],"doi":["10.1007/s12022-020-09645-y"]}}